Literature DB >> 18682919

Activation of G proteins and extracellular signal-regulated kinase 1/2 phosphorylation via human dopamine D4.4 receptors: differential pathway-dependent potencies of receptor agonists.

Peter Heusler1, Liesbeth Bruins Slot, Isabelle Rauly-Lestienne, Christiane Palmier, Stéphanie Tardif, Amélie Tourette, Marie-Christine Ailhaud, Didier Cussac.   

Abstract

Agonist activity at recombinant human dopamine D4.4 receptors was compared in stably transfected CHO cells using two functional readouts: G protein activation by [35S]GTPgammaS binding and phosphorylation of extracellular signal-regulated kinase 1/2 (pERK1/2). Results with a large series of agonists reveal markedly higher relative agonist efficacy in the pERK1/2 assay compared with [35S]GTPgammaS binding, while potencies were generally higher in the latter readout. Whereas efficacies were highly correlated when comparing both tests, potencies determined using the pERK1/2 assay were neither correlated with those for G protein activation nor with binding affinities. In order to examine if these differences may be attributable to distinct assay conditions (5 min incubation for pERK1/2 compared with binding equilibrium conditions for [35S]GTPgammaS), selected compounds were tested in a modified short-duration [35S]GTPgammaS binding assay. In these experiments, potencies were generally reduced; however, compounds exhibiting comparably high potency in the pERK1/2 assay were not affected by this duration-dependent potency shift. We conclude that assay parameters such as signal amplification and incubation time have to be considered with respect to the appropriate choice of experimental approaches that best reflect agonist activity at dopamine D4 receptors in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18682919     DOI: 10.1007/s00210-008-0333-4

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  45 in total

1.  Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors.

Authors:  Didier Cussac; Delphine Duqueyroix; Adrian Newman-Tancredi; Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2002-04-30       Impact factor: 4.530

Review 2.  The classification of seven transmembrane receptors in recombinant expression systems.

Authors:  T Kenakin
Journal:  Pharmacol Rev       Date:  1996-09       Impact factor: 25.468

3.  Dopamine D(4) and D(2L) Receptor Stimulation of the Mitogen-Activated Protein Kinase Pathway Is Dependent on trans-Activation of the Platelet-Derived Growth Factor Receptor.

Authors:  J N Oak; N Lavine; H H Van Tol
Journal:  Mol Pharmacol       Date:  2001-07       Impact factor: 4.436

4.  Ligand-directed signaling at the beta3-adrenoceptor produced by 3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate (SR59230A) relative to receptor agonists.

Authors:  Masaaki Sato; Takahiro Horinouchi; Dana S Hutchinson; Bronwyn A Evans; Roger J Summers
Journal:  Mol Pharmacol       Date:  2007-08-23       Impact factor: 4.436

5.  Comparative pharmacology of human dopamine D(2)-like receptor stable cell lines coupled to calcium flux through Galpha(qo5).

Authors:  Robert B Moreland; Masaki Nakane; Diana L Donnelly-Roberts; Loan N Miller; Renjie Chang; Marie E Uchic; Marc A Terranova; Earl J Gubbins; Rosalind J Helfrich; Marian T Namovic; Odile F El-Kouhen; Jeffrey N Masters; Jorge D Brioni
Journal:  Biochem Pharmacol       Date:  2004-08-15       Impact factor: 5.858

6.  Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.

Authors:  Liesbeth A Bruins Slot; Luc De Vries; Adrian Newman-Tancredi; Didier Cussac
Journal:  Eur J Pharmacol       Date:  2006-02-21       Impact factor: 4.432

7.  Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors.

Authors:  Mounia Azzi; Pascale G Charest; Stéphane Angers; Guy Rousseau; Trudy Kohout; Michel Bouvier; Graciela Piñeyro
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-17       Impact factor: 11.205

8.  The world-wide distribution of allele frequencies at the human dopamine D4 receptor locus.

Authors:  F M Chang; J R Kidd; K J Livak; A J Pakstis; K K Kidd
Journal:  Hum Genet       Date:  1996-07       Impact factor: 4.132

9.  Kinetic analysis of the interactions of agonists and antagonists with beta adrenergic receptors.

Authors:  M L Contreras; B B Wolfe; P B Molinoff
Journal:  J Pharmacol Exp Ther       Date:  1986-10       Impact factor: 4.030

10.  Agonists activate Gi1 alpha or Gi2 alpha fused to the human mu opioid receptor differently.

Authors:  Dominique Massotte; Karl Brillet; Brigitte Kieffer; Graeme Milligan
Journal:  J Neurochem       Date:  2002-06       Impact factor: 5.372

View more
  1 in total

1.  Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors.

Authors:  Martyn Wood; Vanessa Dubois; Dieter Scheller; Michel Gillard
Journal:  Br J Pharmacol       Date:  2015-01-13       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.